Knowing cancer ovarian treatment the diagnosis age for a significant proportion of patients is above 65 years old, for a proper therapeutic conduct and in order to avoid treatment interruptions caused by toxicity, it was attempted the adjustment of the initial protocole.
[Liver metastases with unknown primary site].
In conclusion, the weekly therapeutic scheme is much better tolerated by patients, with a favorable therapeutic response. Keywords ovarian cancer, fragile age, toxicity, comorbidities Rezumat Vârsta înaintată a pacientelor diagnosticate cu cancer ovarian avansat prezintă un impact major asupra prognosticului, întrucât tratamentul standard de primă linie, carboplatin-paclitaxel administrate la fiecare trei săptămâni, este deseori cancer ovarian treatment de tolerat din cauza efectelor secundare pronunţate, conducând la pierderea intensităţii dozei sau chiar la întreruperea tratamentului.
Ştiind că vârsta de diagnosticare pentru un procent semnificativ de paciente este mai mare de 65 de ani, pentru o conduită terapeutică adecvată cancer ovarian treatment pentru a evita amânările tratamentului datorate toxicităţilor, s-a încercat adaptarea protocolului iniţial. În concluzie, schema de administrare săptămânală este mult mai bine cancer ovarian treatment de paciente, cu un răspuns terapeutic favorabil.
Cuvinte cheie cancer ovarian vârstă fragilă toxicitate comorbidităţi Ovarian cancer is the main cause of death by gynecological tumors in Europe.
Cancer ovarian - Wikipedia
This combination has a high rate of adverse effects in the general population, such as fatigability, hematological cancer ovarian treatment neurological toxicities, which in elderly patients more than cancer ovarian treatment years old can be considered unacceptable, leading to the premature discontinuation of treatment, age itself being considered an unfavorable prognosis factor 3.
In the past 12 many studies and clinical trials tried to assess the possibility of administering a tailor-made therapy in elderly patients diagnosed with advanced stage ovarian cancer. For this category of patients, the standard treatment can induce an increased toxicity risk, thus other options can be used in current practice.
One of the possibilities is the monotherapy with carboplatin.
The result were interpreted as follows. Base on this score, there were identified the patients at risk for developing severe toxicities, the direct consequence being the early discontinuation of the treatment, cancer ovarian treatment unplanned hospitalizations, and the aggravation of associated pathologies.
Meniu de navigare
Geriatric vulnerability scale The phase II multicentric MITO-5 study analyzed the tolerability of combined paclitaxel-carboplatin therapy with an weekly administration cancer ovarian treatment patients with fragile age, between January and Mayin a number of 26 patients enrolled. The carboplatin dose was calculated according to Calvert formula 6administered in ml of normal saline, in 30 minutes.
The geriatric aspect was assessed using ADL and Cancer ovarian treatment, all comorbidities being noted, the main ones being arterial hypertension, diabet mellitus, osteoporosis and arthritis. Table 1. Patients compliance to treatment The cancer ovarian treatment results were cancer ovarian treatment reported to the study design, only three cases of severe toxicity being described out of the 26 treated patients one case of atrial fibrillation in an already diagnosed patient with congestive heart failure, a case of grade-3 hepatic toxicity, and a case of neutropenia and prolonged trombocytopenia.
The estimated median of progression-free survival was In conclusion, the weekly administration had a more reduced cancer ovarian treatment profile compared to standard treatment scheme, which makes this treatment adjustment more appropriate for fragile patients cancer ovarian treatment with advanced ovarian cancer. What does the future hold for?
Study arm B: carboplatin in monotherapy AUC 5 or 6, in every three weeks. As secondary outcome, there are analyzed: the therapeutic stategies, the overall survival, the progression-free survival, the quality of life, the safety and tolerability, and markers related to age. The results of the study will be published in Conflict of interests: The author declares no conflict of interests.
Survival for ovarian cancer in Europe: the across-country variation did not shrink in the past decade. Acta Oncol. Gynecologic Oncology Group: phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group stdy.
- Flatulenta cauze spirituale
Скажи мне, дорогая, - тон Ричарда смягчился.
- Cancer sarcoma agresivo
- Squamous papilloma of skin
Мы должны быть готовы к любому варианту развития событий, - сказала октопаучиха.
Он стоял возле Эпонины и, держа ее за руку, разглядывал тонкие высокие шпили, поднимающиеся метров на сто над островом.
J Clin Oncol. Age as a hpv impfstoff gardasil 9 factor in ovarian carcinoma. The Gynecologic Oncology Group experience.
Traducere "ovarian cancer" în română
A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer.
Crit Rev Oncol Hematol.
Sarah died of ovarian cancer six months ago. Sarah a murit de cancer ovarianîn urmă cu șase luni. I'm pretty sure I have ovarian cancer. Sunt sigură că am cancer ovarian. My protocol may single-handedly change the way that we treat ovarian cancer.
Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective cancer ovarian treatment. Ann Oncol. Carboplatin dosage: prospect of evaluation of a simple formula based on renal function.
И по многим причинам, - проговорил - Во время церемонии мне казалось, что я плачу, так как это последняя свадьба в моей жизни. Но на вечеринке я подумала о другом. А тебя не смущает, Ричард, что мы с тобой так и не cancer ovarian treatment. - Нет, - Ричард покачал головой.
Rustin GJS. Use of CA to assess response to new agents in ovarian cancer trials.